QURE
NASDAQ
$39.70
uniQure N.V. (QURE)
uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $64.87 (+63.40%)
Market Cap
$2.58B
Free Cash Flow Yield
-6.68%
Beta (5Y)
0.98
Price Chart
Valuation
Market Cap$2.58B
Forward P/E27.93
P/S157.78
P/B18.92
Profitability
Total Revenue (TTM)$18M
Gross Profit (TTM)-$114M
EBITDA-$179M
Operating Margin-1321%
EPS-$3.43
Financial Health
Debt-to-Equity33.4%
Free Cash Flow Yield-6.68%
Growth & Risk
EPS 5Y CAGR+2.11%
Revenue 5Y CAGR-13.73%
FCF 5Y CAGR+2.35%
Beta (5Y)0.98
Sharpe Ratio1.09